BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Atirmociclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Atirmociclib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06239467-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atirmociclib: Phase 1 readout est. (NCT06239467)
DESCRIPTION:Atirmociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advance
 d Breast Cancer\nEstimated primary completion: 31 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06239467
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05262400-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:Atirmociclib: Phase 1/2 readout est. (NCT05262400)
DESCRIPTION:Atirmociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study to Learn About the Study Medicine (Called PF-07220060 in C
 ombination With PF-07104091) In Participants With Breast Cancer and Solid 
 Tumors\nEstimated primary completion: 26 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05262400
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05216432-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Atirmociclib: Phase 1 readout est. (NCT05216432)
DESCRIPTION:Atirmociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: First-in-Human Study of Mutant-selective PI3Kα Inhibitor\, RLY-2608
 \, as a Single Agent in Patients With Advanced Solid Tumors and in Combina
 tion With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients Wit
 h Advanced Solid Tumors or Advanced Breast Cancer\nEstimated primary compl
 etion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atirmociclib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05216432
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677358-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20270814
DTEND;VALUE=DATE:20270815
SUMMARY:Atirmociclib: Phase 1 readout est. (NCT07677358)
DESCRIPTION:Atirmociclib\, phase 1.\nStudy: A Study to Learn How the Study 
 Medicine Called Atirmociclib is Handled by the Body in People With Normal 
 Liver Function and Different Levels of Liver Disease\nEstimated primary co
 mpletion: 14 August 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atirmociclib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07677358
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07427394-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20271228
DTEND;VALUE=DATE:20271229
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT07427394)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Evaluate the Safety and Tolerability of Camizestrant in Com
 bination With Atirmociclib in Women With Advanced Breast Cancer\nEstimated
  primary completion: 28 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07427394
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508906-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Atirmociclib: Phase 1 readout est. (NCT05508906)
DESCRIPTION:Atirmociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribocic
 lib\, Alpelisib\, Everolimus\, or Atirmociclib in ER+\, HER2- Breast Cance
 r\nEstimated primary completion: 31 December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05508906
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760637-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20290102
DTEND;VALUE=DATE:20290103
SUMMARY:Atirmociclib: Phase 3 readout est. (NCT06760637)
DESCRIPTION:Atirmociclib\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-
 negative Breast Cancer Who Have Not Received Anticancer Treatment for Adva
 nced/Metastatic Disease\nEstimated primary completion: 2 January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06760637
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimat
 ed primary completion: 27 August 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04557449-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20291007
DTEND;VALUE=DATE:20291008
SUMMARY:Atirmociclib: Phase 2 readout est. (NCT04557449)
DESCRIPTION:Atirmociclib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Study to Test the Safety and Tolerability of PF-07220060 in Particip
 ants With Advance Solid Tumors\nEstimated primary completion: 7 October 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/atirmociclib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04557449
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897721-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20300322
DTEND;VALUE=DATE:20300323
SUMMARY:Atirmociclib: Phase 1 readout est. (NCT07897721)
DESCRIPTION:Atirmociclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-08165784 in Peop
 le With PIK3CA-Mutated Advanced or Metastatic Solid Tumors\nEstimated prim
 ary completion: 22 March 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/atirmociclib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07897721
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Atirmociclib: Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Atirmociclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Patients With Metastatic or Locally Advanced Breast Cancer\
 nEstimated primary completion: 30 September 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/atirmociclib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT03424005
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890597-9131@assetmemo.bio
DTSTAMP:20261121T004536Z
DTSTART;VALUE=DATE:20320413
DTEND;VALUE=DATE:20320414
SUMMARY:Atirmociclib: Phase 3 readout est. (NCT07890597)
DESCRIPTION:Atirmociclib\, phase 3.\nStudy: A Study of a Medicine Called At
 irmociclib in Combination With Giredestrant in Adult Participants With ER-
 positive\, HER2-negative Early-stage Breast Cancer\nEstimated primary comp
 letion: 13 April 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/atirmociclib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07890597
URL:https://assetmemo.bio/drug/atirmociclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
